Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2017 ASCO Annual Meeting!


Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Type: Oral Abstract Session

Time: Tuesday June 6, 9:45 AM to 12:45 PM

Location: E450ab

Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial.

Sub-category:
Chronic Leukemia—CML and Hairy Cell

Category:
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Meeting:
2017 ASCO Annual Meeting

Abstract No:
7002

Citation:
J Clin Oncol 35, 2017 (suppl; abstr 7002)

Author(s): Jorge E. Cortes, Carlo Gambacorti-Passerini, Michael W.N. Deininger, Michael J. Mauro, Charles Chuah, Dong-Wook Kim, Laurence Reilly, Allison Marianne Jeynes-Ellis, Eric Leip, Nathalie Bardy-Bouxin, Andreas Hochhaus, Tim H. Brümmendorf, On Behalf of the BFORE Study Investigators; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Milano-Bicocca, Monza, Italy; University of Utah, Salt Lake City, UT; Memorial Sloan-Kettering Cancer Center, New York, NY; Singapore General Hospital, Duke-NUS Graduate Medical School, Singapore, Singapore; Seoul St. Mary’s Hospital, Seoul, South Korea; Avillion LLP, London, United Kingdom; Pfizer Inc., Cambridge, MA; Pfizer Global Research and Development, Paris, France; Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany; Universitätsklinikum RWTH Aachen, Aachen, Germany

Abstract Disclosures

Abstract:

Background: BOS is a potent, dual SRC/ABL tyrosine kinase inhibitor approved for treatment (tx) of adults with Ph+ CML resistant/intolerant to prior therapy. We assessed the efficacy and safety of BOS vs IM for first-line tx of chronic phase (CP) CML. Methods: In this ongoing, multinational, phase 3, open-label study, 536 patients (pts) with newly diagnosed CP CML were randomized 1:1 to BOS 400 mg QD (n = 268) or IM 400 mg QD (n = 268 [3 not treated]). Per protocol, efficacy was assessed in a modified intent-to-treat (ITT) population of 487 Ph+ pts (BOS, n = 246; IM, n = 241) with e13a2/e14a2 transcripts; results in full ITT will also be presented. Results: After≥12 mo of follow-up, 78% of BOS and 73.2% of IM pts remain on tx with median tx durations of 14.1 and 13.8 mo, respectively. Major molecular response (MMR) rate at 12 mo (primary endpoint) was significantly higher with BOS vs IM (47.2% vs 36.9%; P= 0.02). Time to MMR was shorter for BOS (hazard ratio [HR] 1.34; P< 0.02). Rate of complete cytogenetic response (CCyR) by 12 mo was also significantly higher with BOS vs IM (77.2% vs 66.4%; P< 0.008), with time to CCyR shorter for BOS (HR 1.38; P≤0.001). Rates of BCR-ABL transcripts≤10% (Intl Scale) at 3 mo (75.2% vs 57.3%), MR4 at 12 mo (20.7% vs 12%) and MR4.5 at 12 mo (8.1% vs 3.3%) were higher with BOS vs IM, respectively (all P< 0.025). 1 BOS pt and 4 IM pts discontinued tx due to progression to accelerated or blast phase. There were no deaths within 28 d of last dose of BOS and 4 with IM. Safety data were consistent with known safety profiles of BOS and IM. 12.7% of BOS and 8.7% of IM pts discontinued due to drug-related toxicity. Gr≥3 diarrhea (7.8% vs 0.8%) and increased alanine (19% vs 1.5%) and aspartate (9.7% vs 1.9%) aminotransferase levels were more common with BOS. Cardio-, peripheral- and cerebrovascular events were infrequent (3%, 1.5% and 0% BOS vs 0.4%, 1.1% and 0.4% IM; gr≥3: 1.5%, 0% and 0% vs 0%, 0% and 0.4%). Conclusions: Pts on BOS had significantly higher rates of 12-mo MMR and CCyR and achieved responses faster than those on IM, but had higher incidence of gastrointestinal events and transaminase elevations. Results suggest BOS may be an important tx option for pts with newly diagnosed CP CML. Funding. Avillion, Pfizer. Clinical trial information: NCT02130557.

 
Other Abstracts in this Sub-Category:

 

1. Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).

Meeting: 2017 ASCO Annual Meeting Abstract No: 7012 First Author: Hagop M. Kantarjian
Category: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant - Chronic Leukemia—CML and Hairy Cell

 

2. Ten-year survival after randomized comparison of imatinib (IM) 400 mg vs. IM 800 mg vs. IM + IFN vs. IM + Ara C vs. IM after IFN in chronic myeloid leukemia (CML).

Meeting: 2017 ASCO Annual Meeting Abstract No: 7049 First Author: Ruediger Hehlmann
Category: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant - Chronic Leukemia—CML and Hairy Cell

 

3. Impact of early landmark responses with ponatinib on 4-yr outcomes in CP-CML patients (pts) in PACE, a pivotal phase II trial.

Meeting: 2017 ASCO Annual Meeting Abstract No: 7050 First Author: Martin Mueller
Category: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant - Chronic Leukemia—CML and Hairy Cell

 

More...